Sun Pharmaceutical Industries Ltd
The live share price of Sun Pharmaceutical Industries Ltd (SUNPHARMA) as on 30 May 10:26am is ₹959.6 from NSE/BSE.
SUNPHARMA NSE
₹959.6 ▼-0.91% (-8.85)
As on May 30, 2023 03:56 PM IST
Key Metrics
PE Ratio
27.27
PB Ratio
4.55
Dividend Yield
1.19%
Sector PB
4.49
Sector PE
33.72
Sector Div Yld
0.82%
Dividend Yield
Dividend per share for the most recent financial year divided by the close price
About
Sector
Health Care
Industry
Pharmaceuticals
Market Cap
Largecap, ₹2,32,363 Cr
Sun Pharmaceutical Industries Limited is a pharmaceuticals company which offers generics, branded generics, specialty products, over-the-counter products, anti-retroviral and APIs.
The following charts display the financial performance of the Sun Pharmaceutical Industries Ltd (SUNPHARMA) stock, including the year-on-year Income Statement , Balance Sheet , Cash Flow Statement and Shareholding pattern.
Furthermore, under the Peers section, you can find stocks that are similar to Sun Pharmaceutical Industries Ltd (SUNPHARMA), and their live stock price and performance at a glance. Click on any peer stock to navigate to that stock’s live price page.
✅ If you’re new to investing in the stock market, and/or are unsure about your investment options, you can explore smallcases.
A smallcase is a readymade stock/ETF portfolio (also known as a stock basket) that is based on an investment idea, theme or strategy. Examples of popular smallcases include All Weather Investing , Equity and Gold , Top 100 Stocks , Green Energy and Value & Momentum.
All smallcases are created and managed by SEBI-registered investment experts.
To invest in smallcases, all you need is a demat/trading account. You retain complete ownership of the smallcase’s constituent stocks or ETFs, as they are directly credited to your broking account. You can choose from over 500+ smallcases across 180+ smallcase managers to start your investment journey.
Sector
Health Care
Industry
Pharmaceuticals
Market Cap
Largecap, ₹2,32,363 Cr
Financials
Income Statement
| (INR) | Y/Y Change | |
| Revenue | 44,520 Cr | +12.06% |
| Operating Expense | 32,410 Cr | +352.08% |
| Net Income | 8,521 Cr | +160.38% |
| Net Profit Margin | 19.14% | +132.28% |
| Earning Per Share | 35 | +158.79% |
| EBITDA | 12,109 Cr | +79.34% |
Balance sheet
| (INR) | Y/Y Change | |
| Cash & short-term Inv | 12,667 Cr | +32.29% |
| Total Assets | 69,768 Cr | +3.17% |
| Total Liabilities | 18,701 Cr | +3.08% |
| Total Equity | 51,066 Cr | +3.21% |
| Shares Outstanding | 239.93 Cr | - |
| Price to Book | 4.27 | +44.18% |
| Return on Assets | 4.76% | +11.21% |
| Return on Capital | 9.02 Cr | +51.85% |
Cash Flows
| (INR) | Y/Y Change | |
| Net Income | 8,521 Cr | +160.38% |
| Cash from Operations | 8,984 Cr | +45.61% |
| Cash from Investing | -5,555 Cr | -1466.65% |
| Cash from Financing | -5,193 Cr | -13.16% |
| Net Change in Cash | -1,764 Cr | -395.9% |
| Free Cash Flow | 7,489 Cr | +49.78% |
Peers
CIPLA
Cipla Ltd
PE Ratio
27.52
1Y Return
▼-2.73%
DRREDDY
Dr Reddy's Laboratories Ltd
PE Ratio
16.8
1Y Return
▲3.4%
TORNTPHARM
Torrent Pharmaceuticals Ltd
PE Ratio
69.48
1Y Return
▲18.78%
MANKIND
Mankind Pharma Ltd
PE Ratio
0
1Y Return
▼-4.67%
Latest News
Stocks to watch: Adani Ports, NMDC, HDFC Life, Apollo Hospitals, PTC Inds
1 hour ago on Business Standard
Change since news 0%
Stocks to watch on May 31, 2023: From Adani Ports to Sun Pharma, here are top stocks to watch in Wednesday’s trading session
‘Sun Pharma eyes deals to push specialty play, EM business’
9 hours ago on Economic Times
Change since news 0%
Sun Pharma, India’s largest drugmaker, is looking at acquisitions to boost its specialty pipeline and strengthen emerging markets business. “Our focus on M&A will be on augmenting the pipeline for specialty and further strengthening our footprint in emerging markets,” said CS Muralidharan, chief fin…
Sun Pharmaceutical Gets China NMPA Approval For Plaque Psoriasis
13 hours ago on Bloomberg Quint
Change since news ▲0.91%
The product under the brand name Ilumetri has been approved by China’s National Medical Products Administration.
Sun Pharma receives China NMPA’s nod for treatment of plaque psoriasis
13 hours ago on Business Standard
Change since news ▲0.91%
Ilumetri is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
Will work with Taro-appointed committee for “win-win” transaction for both: Sun Pharma CFO
14 hours ago on The Hindu Businessline
Change since news ▲0.91%
Sun’s CFO explained getting full control of Taro would enable, among other things, the delisting of the company from NYSE
Stock market update: Stocks that hit 52-week lows on NSE in today’s trade
15 hours ago on Economic Times
Change since news ▲0.91%
Hindalco, Adani Ent., Tech Mahindra, Tata Steel and Sun Pharma were among the top losers on NSE in today’s trade.
Sensex, Nifty rise for 4th straight session
16 hours ago on Economic Times
Change since news ▲0.91%
From the Sensex pack, ITC, Bajaj Finserv, Kotak Bank, and Bajaj Finance were the top gainers, rising 1-2%. Axis Bank, HCL Tech, Wipro, UltraTech Cement, and Maruti also closed with gains. On the flip side, Tata Steel, Tech Mahindra, Sun Pharma, Nestle, L&T, and SBI closed with losses.
Sun Pharma, Philogen join hands to commercialise skin cancer drug in Europe
18 hours ago on Business Standard
Change since news ▲0.91%
Sun Pharmaceutical Industries on Tuesday said it has entered into a licensing pact with Philogen SpA to commercialise under-development skin cancer drug in Europe, Australia and New Zealand.
Sun Pharma, Philogen join hands to commercialise skin cancer drug in Europe, Australia, New Zealand
18 hours ago on Economic Times
Change since news ▲0.91%
Sun Pharmaceutical Industries on Tuesday said it has entered into a licensing pact with Philogen SpA to commercialise under-development skin cancer drug in Europe, Australia and New Zealand. The companies have come together to commercialise Philogen’s speciality product Nidlegy, an anti-cancer bioph…
Sun Pharma Q4 Results Review - US/EM/ROW Drive Earnings For The Quarter: Motilal Oswal
19 hours ago on Bloomberg Quint
Change since news ▲0.91%
Sun Pharma Q4 Results Review - US/EM/ROW Drive Earnings For The Quarter: Motilal Oswal
FAQs on Sun Pharmaceutical Industries Ltd
How to buy Sun Pharmaceutical Industries Ltd stocks?
You can easily buy the stocks/shares of Sun Pharmaceutical Industries Ltd (SUNPHARMA) through either a broker or a financial institution by opening a Demat & Trading account online via smallcase.
What is the Share Price of Sun Pharmaceutical Industries Ltd?
The stock price of Sun Pharmaceutical Industries Ltd as on 30 May 2023 is ₹959.6
What is the 52-week High and Low of Sun Pharmaceutical Industries Ltd?
The 52-week high and low of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is ₹1,072.15 and ₹789.9.
What is the PE and PB ratio of Sun Pharmaceutical Industries Ltd?
The P/E (price-to-earnings) and P/B (price-to-book) ratios of Sun Pharmaceutical Industries Ltd are 27.27 and 4.55 respectively.
What are the peers or stocks similar to Sun Pharmaceutical Industries Ltd?
The peers or stocks similar to Sun Pharmaceutical Industries Ltd are Cipla Ltd, Dr Reddy's Laboratories Ltd, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd and many others. smallcase also offers over 200 readymade stock baskets managed by 180+ SEBI-registered investment experts. These stock portfolios are based on a theme, idea or strategy. You can use smallcase to start investing in diversified stock baskets.
Which sector does Sun Pharmaceutical Industries Ltd belong to?
Sun Pharmaceutical Industries Ltd (SUNPHARMA) belongs to the Pharmaceuticals sector.
What is the Market Cap of Sun Pharmaceutical Industries Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is ₹2,32,363 Cr as of 30 May 2023
Can't decide whether or not to buy Sun Pharmaceutical Industries Ltd stocks? ⭐️
Worry no more! smallcase offers readymade stock baskets/portfolios that are based on an theme, idea or strategy. You can choose from more than 500+ stock portfolios managed by 180+ SEBI-registered investment experts.
smallcase Technologies Private Limited
#51, 3rd Floor, Le Parc Richmonde,
Richmond Road, Shanthala Nagar,
Richmond Town, Bangalore - 560025